Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.
Phase:
PHASE3
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborator:
Shenzhen Medical Academy of Research and Translation